Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study

<table>The patients’ health related quality of life measured by SF-36. The graph shows the mean scores for the eight SF-36 domains for the normal population and the patients with AS at baseline, at 16 weeks, and at 56 weeks. A significant improvement in patients’ health related quality of life was observed at weeks 16 and 56 as compared with baseline. </table>

Mediators of Inflammation

fig5

Figure 5

Figure 5: Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study 